FDA Approves Corlanor® (ivabradine) To Reduce The Risk Of Hospitalization For Worsening Heart Failure In Patients With Chronic Heart Failure

Industry News

The FDA approved Corlanor (ivabradine) to reduce the risk of hospitalization for worsening heart failure in patients with chronic heart failure.  Corlanor is an oral medication made by Amgen, a biotech giant based in Thousand Oak, California.  Corlanor reduces the spontaneous pacemaker activity of the heart by blocking a specific type of channel responsible for regulation of heart rate leading to amelioration of tachycardia in heart failure.  Heart failure is a serious condition resulting from damages to the heart such as high blood pressure, diabetes, coronary heart disease and heart attacks.  Approximately 5.1 million people in the US have heart failure and about half of these patients die within 5 years of diagnosis despite of standard treatments.  Hospitalization constitutes the majority of the economic cost treating chronic heart failure.  The approval is based on Phase III clinical trial demonstrating that Corlanor significantly reduced the time to first occurrence of hospitalization for worsening of heart failure in comparison to placebo control.  Corlanor is the first FDA-approved medicine indicated for chronic heart failure in nearly a decade.


Related Links:


Subscribe to WXPress

Receive our newsletter and information on upcoming events.